New hope for rare cancer: drug combo shows promise in advanced angiosarcoma
NCT ID NCT01303497
First seen Mar 27, 2026 · Last updated May 25, 2026 · Updated 6 times
Summary
This study tested two treatments for people with advanced angiosarcoma, a rare cancer of blood vessels, that cannot be removed by surgery. Participants received either a chemotherapy drug called paclitaxel alone or paclitaxel plus another drug called bevacizumab. The goal was to see if the combination helped keep the cancer from growing for at least 6 months. The study enrolled 70 adults and has been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre René Gauducheau
Saint-Herblain, 44805, France
-
Centre Val d'Aurelle
Montpellier, 34298, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31052, France
-
Institut Curie
Paris, 75005, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, 42270, France
Conditions
Explore the condition pages connected to this study.